Protagonist Therapeutics Reports Q1 Profit, Secures Major Rusfertide Royalty Deal with Takeda, and ICOTYDE FDA Approval

summarizeSummary

Protagonist Therapeutics reported a profitable Q1 2026, fueled by a $50 million milestone for ICOTYDE's FDA approval, and announced a strategic opt-out from the Rusfertide profit-sharing deal with Takeda, triggering a $200 million payment and securing significant future royalties and milestones.

check_boxKey Events

• Q1 2026 Financial Turnaround

  The company reported a net income of $3.8 million for Q1 2026, a significant improvement from a net loss of $11.7 million in Q1 2025. License and collaboration revenue nearly doubled to $56.4 million, up 99% year-over-year.

• ICOTYDE FDA Approval & Milestone

  Protagonist earned a $50.0 million milestone payment in March 2026 following FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis. The company remains eligible for up to $580.0 million in future development and sales milestones, plus tiered royalties (6-10%).

• Strategic Rusfertide Opt-Out with Takeda

  As a subsequent event on April 28, 2026, Protagonist exercised its right to opt out of the U.S. profit and loss sharing arrangement for Rusfertide with Takeda. This triggers an immediate $200.0 million payment and makes the company eligible for an additional $200.0 million opt-out fee and a $75.0 million milestone upon FDA approval of rusfertide.

• Significant Future Rusfertide Royalties & Milestones

  Following the opt-out, Protagonist is eligible to receive tiered royalties ranging from 14% to 29% on annual net worldwide sales of Rusfertide, with an approximate 21% weighted-average royalty rate at $1.5 billion in annual net sales. The company is also eligible for up to $775.0 million in sales milestone payments.

auto_awesomeAnalysis

Protagonist Therapeutics delivered a strong first quarter, turning a net loss into a profit, driven by a significant milestone payment for ICOTYDE's FDA approval. The most impactful news, disclosed as a subsequent event, is the company's decision to opt out of the U.S. profit-sharing arrangement for Rusfertide with Takeda. This strategic move immediately triggers a $200 million payment and positions Protagonist to receive substantial future milestone payments and tiered royalties (14-29%) on worldwide net sales, de-risking commercialization and providing a clear, high-value revenue stream for a key asset. The Rusfertide NDA also received Priority Review with a Q3 2026 PDUFA date, indicating near-term commercial potential. While the filing also disclosed new 10b5-1 selling plans by the CEO and a Director, which represent a notable amount of potential insider selling, the overwhelming positive financial and strategic developments overshadow this, especially as the stock is trading near its 52-week high.